Main > A1. CORP. INDEX. Sn-Sz > Spectrum Pharmaceuticals/P C2

---

This data is not available for free

Spectrum Pharmaceuticals/P C2's subsections
2008. 03.07. Onco.>Sarcoma
2011. 05.30. Onco.>Taxane
2012. 01.31. Onco.>Neutropenia
2012. 03.27. Onco.>Lymphoma>Ib
2012. 09.11. Exec VP & COO
2012. 10.08. Onco.>Lymphoma>Pr
2012. 10.29. Sr VP Sales &
2012. 11.01. Expansion...
2013. 01.17. Patent
2013. 01.31. Onco.>Bladder C.
2013. 07.17. Corp. Acq.
2013. 09.03. Onco.>Ph- ALL
2014. 07.03. Onco.>Lymphoma>Be
2016. 03.15. Onco.>MM
2018. 10.23. Onco.>Levoleucovorin
2019. 01.17. Sale of 7 Products to
2022. 09.09. USA FDA Approval
2022. 10.21. eflapegrastim-xnst>Ava
2023. 04.25. Acq By Assertio Therap
Patents
Web-Site

Spectrum Pharmaceuticals/P C2's products
This section has no products